Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813

Biomaterials

Volumn 31, Issue 25, 2010, Pages 6567-6573

  Melancon, Marites P ^a   Lu, Wei ^a   Huang, Qian ^a   Thapa, Prakash ^a   Zhou, Dapeng ^a   Ng, Chaan ^a   Li Chun, C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED MACROPHAGES; ANTI-CANCER THERAPIES; ANTI-TUMORS; CONTRAST AGENT; EX-VIVO; GROWTH FACTOR; IMAGE RESPONSE; IMMUNOHISTOCHEMICAL STAINING; IMMUNOTHERAPEUTICS; IN-VIVO; INTRAVENOUS INJECTIONS; L-GLUTAMIC ACIDS; MAGNETOOPTICAL IMAGING; MR IMAGING; NEAR-INFRARED FLUORESCENCE IMAGING; NON-INVASIVE ASSESSMENTS; TARGETED IMAGING; TUMOR GROWTH; TUMOR NECROSIS;

ANIMALS; GADOLINIUM; MACROPHAGES; OPTICAL IMAGE STORAGE; RESONANCE; TUMORS;

MAGNETIC RESONANCE IMAGING;

ANTIGEN; CD163 ANTIGEN; CD169 ANTIGEN; CD68 ANTIGEN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLY(GLUTAMIC ACID) GADOLINIUM CHELATED 4 AMINOBENZYLDIETHYLENETRIAMINEPENTAACETIC ACID NIR 813; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; GADOLINIUM; INDOLE DERIVATIVE; NIR 813; POLYGLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; EX VIVO STUDY; FLUORESCENCE IMAGING; GLIOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; M2 MACROPHAGE; MACROMOLECULE; MACROPHAGE ACTIVATION; MOUSE; NICK END LABELING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; PRIORITY JOURNAL; RAT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; MACROPHAGE; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CONTRAST MEDIA; GADOLINIUM; INDOLES; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS; POLYGLUTAMIC ACID; RATS;

ANIMALIA; RATTUS;

EID: 77953959072     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.05.001     Document Type: Article

References (19)

1. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124(2):263-266.
2. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78.
3. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3(1):23-35.
4. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196(3):254-265.
5. van der Bij G.J., Bogels M., Oosterling S.J., Kroon J., Schuckmann D.T., de Vries H.E., et al. Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases. Cancer Lett 2008, 262:77-86.
6. Forssell J., Oberg A., Henriksson M.L., Stenling R., Jung A., Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007, 13(5):1472-1479.
7. + T cell tolerance in cancer. Nat Med 2007, 13(7):828-835.
8. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42(6):717-727.
9. Allavena P., Signorelli M., Chieppa M., Erba E., Bianchi G., Marchesi F., et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005, 65(7):2964-2971.
10. Joseph I.B., Isaacs J.T. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 1998, 90(21):1648-1653.
11. Leimgruber A., Berger C., Cortez-Retamozo V., Etzrodt M., Newton A.P., Waterman P., et al. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 2009, 11(5):459-468.
12. Wen X., Jackson E.F., Price R.E., Kim E.E., Wu Q., Wallace S., et al. Synthesis and characterization of poly(l-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent. Bioconjug Chem 2004, 15(6):1408-1415.
13. Melancon M.P., Wang Y., Wen X., Bankson J.A., Stephens L.C., Jasser S., et al. Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping. Invest Radiol 2007, 42(8):569-578.
14. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994, 174(1-2):83-93.
15. Jackson E.F., Esparza-Coss E., Wen X., Ng C.S., Daniel S.L., Price R.E., et al. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int J Radiat Oncol Biol Phys 2007, 68(3):830-838.
16. Landstrom M., Funa K. Apoptosis in rat prostatic adenocarcinoma is associated with rapid infiltration of cytotoxic T-cells and activated macrophages. Int J Cancer 1997, 71(3):451-455.
17. Li C., Yu D.F., Newman R.A., Cabral F., Stephens L.C., Hunter N., et al. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate. Cancer Res 1998, 58(11):2404-2409.
18. Li C., Price J.E., Milas L., Hunter N.R., Ke S., Yu D.F., et al. Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin Cancer Res 1999, 5(4):891-897.
19. Li C., Ke S., Wu Q.-P., Tansey W., Hunter N., Buchmiller L.M., et al. Potentiation of ovarian OCa-1 tumor radioresponse by poly (l-glutamic acid)-paclitaxel conjugate. Int J Radiat Oncol Biol Phys 2000, 48(4):1119-1126.